XML 34 R19.htm IDEA: XBRL DOCUMENT v3.24.3
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues
Revenues from collaboration and license agreements as a percentage of total revenues were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Genentech, Inc.100 %— %98 %— %
Kite Pharma, Inc.— %58 %— %11 %
Biogen MA, Inc.— %4 %— %77 %
Novartis Institutes for BioMedical Research, Inc.— %— %— %7 %
Other license agreements— %38 %2 %5 %
Schedule of Cash and Cash Equivalents
A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):
September 30,
2024		December 31,
2023		September 30,
2023		December 31,
2022
Cash and cash equivalents$39,201 $45,204 $56,514 $100,444 
Non-current restricted cash1,500 1,500 1,500 1,500 
Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows$40,701 $46,704 $58,014 $101,944 
Restrictions on Cash and Cash Equivalents
A reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):
September 30,
2024		December 31,
2023		September 30,
2023		December 31,
2022
Cash and cash equivalents$39,201 $45,204 $56,514 $100,444 
Non-current restricted cash1,500 1,500 1,500 1,500 
Cash, cash equivalents, and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows$40,701 $46,704 $58,014 $101,944